The europe influenza market size was valued at USD 1.39 billion in 2021 and is expected to reach USD 2.6 billion by 2028, at a CAGR of 9.5% during the forecast period 2022-2028. Influenza, commonly referred to as the flu, is a viral infection that occurs in the respiratory system. Type A, Type B, and Type C are the three main influenza viruses that affect humans. The fourth influenza virus, classified as Type D, does not infect people, although it is thought to have the capacity to do so in the future. Coughing, sore throat, runny nose, migraine, sneezing, chest infection, joint aches, and fatigue are all frequent influenza symptoms. In addition, diarrhea and vomiting are two more symptoms seen in youngsters.

View Detailed Report Description at         

There is no single immunization strategy in Europe. As a result, policies within the area varied from nation to country. The European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) provide some standard for member nations. The Europe Influenza market is expanding rapidly as a result of increased government support and increased spending by key market participants in the area. During the projected timeframe, the Europe Influenza Market is expected to rise at a substantial Rate. Factors such as increasing advances in the creation of innovative medications, as well as expanding health infrastructure in various countries throughout the world, are expected to propel the Europe Influenza Market forward in the approaching years. Furthermore, rising healthcare spending, fueled by consumer demand for high-quality services, is expected to help to the Europe Influenza Market's expansion. As per World Bank figures, global health expenditure (as a percentage of GDP) has grown from 9.07 percent in 2001 to 9.85 percent in 2018. Furthermore, rising fear about fatalities caused by different diseases, as well as the demand for treatments that can reduce the infant mortality rate, which was close to 6% (per 1000 people) in 2019, are expected to propel the Europe Influenza Market forward throughout the projected period.

The Global Europe Influenza Market on the basis of type is bifurcated into QUADRIVALENT VACCINE and TRIVALENT VACCINE. On the basis of technology, the market is divided into Egg based technology and cell based technology. On the basis of age group, the market is segmented into Pediatric age group and Adult age group. On the basis of delivery mode, the market is classified into Injection and Nasal spray.

The Europe Influenza Market is broken down by nations including Belgium, Russia, the United Kingdom, Germany, Poland, France, Italy, and the rest of Europe. Owing to the preventative measure of immunization, Russia's influenza pandemic season of 2017-2018 was marked by comparably low morbidity and death.

Request sample report at                     

There are several industry players working in the europe influenza market, which include AstraZeneca (U.K.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline Plc. (U.K.), Novartis AG (Switzerland), Sanofi (France), Protein Sciences Corporation (U.S.), Emergent Biosolutions (U.S.), BioCryst Pharmaceuticals.Inc. (U.S.), and Abbott Laboratories Inc. (U.S.) to name a few.




About Precision Business Insights:

We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.


Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.



Mr. Satya

Precision Business Insights | Toll Free: +1 866 598 1553

Email: [email protected]
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: | D U N S® Number: 852781747